CompanyAPMDNasdaqCambridge, MA

Apnimed

Apnimed develops oral therapies for sleep-related breathing diseases.

SEC EDGAR ClinicalTrials.gov apnimed.com

10-KSep 25Latest SEC filing

Sep 11Latest story

September 2026

Apnimed posts Phase 3 SynAIRgy results for AD109 in obstructive sleep apnea

Sep 11Trial updateAD109 Apnimed

Apnimed's OSA drug NDA accepted by FDA, PDUFA date set for February 2027

Sep 8Quarterly updateAD109 Apnimed

August 2026

Apnimed posts Phase 2 MARIPOSA results showing AD109 cut AHI4 versus placebo

Aug 12Trial updateAD109 AD504

July 2026

Apnimed prices IPO at $16 per share ahead of Nasdaq debut

Jul 31FinancingApnimed

Apnimed files for IPO as FDA reviews Oxnimbi NDA for sleep apnea

Jul 10FinancingApnimed